Christina Haeyoung Yeon, M.D., M.H.M., immigrated to the U.S. from Seoul, Korea, at age 5 and grew up in Riverside, California. She completed the majority of her higher education at the University of California Los Angeles, including a bachelor’s degree in biochemistry, a medical doctorate, an internal medicine residency and a combined medical oncology/hematology fellowship.
Dr. Yeon has practiced medical oncology/hematology in Pasadena, California, since 2004. She has extensive experience in the diagnosis and treatment of all adult malignancies, as well as benign/malignant hematologic disorders, with a special interest in breast oncology.
She has been a key member of City of Hope’s South Pasadena team since joining the practice in 2011. After serving as site lead physician for the South Pasadena clinic starting in 2014, she then became the regional director for the clinical network sites in the San Gabriel Valley in 2018. There are currently six clinical network sites in this region. In her leadership role, she works closely with operations colleagues to oversee and optimize all aspects of care delivery across multiple medical specialties.
In addition to her clinical and leadership duties, Dr. Yeon serves on multiple committees at City of Hope. These include the compliance, credentials, retirement, benefits and physician well-being committees. She has also been elected by her peers to the medical executive committee and the medical group board of directors.
Dr. Yeon has lived locally within the community since 2005. She lives in La Crescenta, California, with her husband and three children.
2015, American Board of Internal Medicine — Subspecialty of Hematology
2014, American Board of Internal Medicine — Subspecialty of Medical Oncology
2001, American Board of Internal Medicine
2022, Masters of Healthcare Management (M.H.M), Eller College of Management, University of Arizona, Tucson, AZ
1998, M.D., UCLA, Los Angeles, CA
1994, B.S., biochemistry, Summa Cum Laude, UCLA, Los Angeles, CA
2001-2004, Fellow, Hematology/Oncology, UCLA, Los Angeles, CA
1999-2001, Resident, Internal Medicine, UCLA, Los Angeles, CA
1998-1999, Intern, Internal Medicine, UCLA, Los Angeles, CA
2019-present, Associate Clinical Professor, Department
of Medical Oncology & Therapeutics Research, City of Hope, South Pasadena and Duarte, CA
2018-present, Regional Director for San Gabriel Valley, City of Hope, South Pasadena, CA
2011-2019, Assistant Clinical Professor, Department
of Medical Oncology & Therapeutics Research, City of Hope, South Pasadena, CA
2004-2011, Physician, Wilshire Oncology Medical Group Inc., Pasadena, CA
Awards & Memberships
American Society of Clinical Oncology
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer. Cancer. 2022 Dec 14. DOI: 10.1002/cncr.34589.
Bosserman LD, Cianfrocca M, Yuh B, Yeon C, Chen H, Sentovich S, Polverini A, Zachariah F, Deaville D, Lee A, Sedrak M, King E, Gray S, Morse D, Glaser S, Bhatt G, Adeimy C, Tan T, Chao J, Nam A, Paz I, Kruper L, Rao P, Sokolov K, Kulkarni P, Salgia R, Yamzon J, Johnson D. Integrating academic and community cancer care and research through multidisciplinary oncology pathways for value-based care: a review and the City of Hope experience. J Clin Med. 2021 Jan 7;10(2):188. DOI: 10.3390/jcm10020188.
Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer. Oncologist. 2020 Oct 24. DOI: 10.1002/onco.13574.
Mortimer JE, Kruper L, Cianfrocca M, Lavasani S, Liu S, Tank-Patel N, Sedrak M, Smith W, Stewart D, Waisman J, Yeon C, Wang T, Yuan Y. Use of HER2-directed therapy in metastatic breast cancer and how community physicians collaborate to improve care. J Clin Med. 2020 June 24;9(6):1984. DOI: 10.3390/jcm9061984.
Liu J, Gutierrez E, Tiwari A, Padam S, Li D, Dale W, Pal SK, Stewart D, Subbiah S, Bosserman LD, Presant C, Phillips T, Yap K, Hill A, Bhatt G, Yeon C, Cianfrocca M, Yuan Y, Mortimer J, Sedrak MS. Strategies to improve participation of older adults in cancer research. J Clin Med. 2020 May 22; 9(5): 1571. DOI: 10.3390/jcm9051571.
Hurria A, Soto Perez de Celis E, Blanchard S, Burhenn P, Yeon C, Yuan Y, Li D, Katheria V, Waisman JR, Luu TH, Somlo G, Noonan AM, Lee T, Sudan N, Chung S, Rotter A, Arsenyan A, Levi A, Mortimer JE. A phase II trial of older adults with metastatic breast cancer receiving nab-paclitaxel: melding the fields of geriatrics and oncology. Clin Breast Cancer. 2019 Apr; 19(2): 89-96. DOI: 10.1016/j.clbc.2018.10.002.
Ashing KT, Cho D, Lai L, Yeung S, Young L, Yeon C, Fong Y. Exploring characteristics, predictors, and consequences of fear of cancer recurrence among Asian-American breast cancer survivors. Psycho-Oncology. 2017 Dec; 26(12): 2253-2260. DOI: 10.1002/pon.4350.
Chung V, Frankel P, Lim D, Yeon C, Leong L, Chao J, Ruel N, Luevanos E, Koehler S, Chung S, Lau SC, Fakih MG. Phase Ib trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma. Oncology 2016 Apr 20, 90(6): 307-312. DOI: 10.1159/000445297.
Lai L, Woo D, Chapman Y, Sudan N, Yeon CH, Trisal V and Waisman JR. Mismatch of available cancer therapeutic trials to patient populations in community practices [abstract]. In: Proc Am Soc Clin Oncol; 2014. Abstract 84.
Chung V, Frankel P, Lim D, Chao J, Yeon CH, Leong L, Kim J, Luevanos E, Rose C and Fakih M. A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399) [abstract]. In: Proc Am Soc Clin Oncol; 2014. Abstract e15007.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Know important info medical history
Show respect for what you say
Spend enough time with you
Rate provider 0-10
Recommend this provider office
Provider explain in way you understand
Provider listen carefully to you
Dr. Yeon is very good at explaining unfortunately at this time we don't have the diagnostics to further clarify the problem, so that was a little disconcerting. Waiting for results as pain continues is frustrating, but all other questions and concerns are addressed. She's super responsive as is her team. - Verified patient
Dr. Yeon provides the best care I have ever had. I feel truly blessed that she is my doctor. - Verified patient
I always know I am in good hands and trust all staff members. - Verified patient
Oftentimes patients feel rushed with little time to discuss concerns. I know physicians currently can be made to feel they're pressured to be speedy. Dr.Yeon listens with an open mind & heart. She provides the information I seek at every appointment. - Verified patient
Dr. Yeon is the best medical oncologist! - Verified patient